Potential antivirals and antiviral strategies against SARS coronavirus infections (Q36441511)

14 August 2017

2 references

22 October 2022

Potential antivirals and antiviral strategies against SARS coronavirus infections (English)

1 reference

14 August 2017

0 references

1 reference

1 reference

Erik De Clercq

1

0 references

publication date

1 April 2006

2 references

Expert Review of Anti-infective Therapy

14 August 2017

22 October 2022

2 references

14 August 2017

22 October 2022

4

1 reference

14 August 2017

291-302

1 reference

14 August 2017

2

1 reference

Coronavirus as a possible cause of severe acute respiratory syndrome

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

A major outbreak of severe acute respiratory syndrome in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

A novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Aetiology: Koch's postulates fulfilled for SARS virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Identification of a new human coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

SARS--beginning to understand a new virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Antivirals and antiviral strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Structural characterization of the SARS-coronavirus spike S fusion protein core.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5' to 3' viral helicases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Expression, purification, and characterization of SARS coronavirus RNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Mutational analysis of the SARS virus Nsp15 endoribonuclease: identification of residues affecting hexamer formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Interferon-beta 1a and SARS coronavirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Therapeutic potential of RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibition of SARS-associated coronavirus infection and replication by RNA interference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Small molecules targeting severe acute respiratory syndrome human coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Structural analysis of inhibition mechanisms of aurintricarboxylic acid on SARS-CoV polymerase and other proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Effects of chloroquine on viral infections: an old drug against today's diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.291

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

21 January 2018

1 reference

12 December 2020

Treatment of SARS with human interferons

1 reference

12 December 2020

New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus

1 reference

12 December 2020

Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

1 reference

12 December 2020

Treatment of severe acute respiratory syndrome with convalescent plasma

1 reference

12 December 2020

Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase

1 reference

12 December 2020

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine

1 reference

12 December 2020

Current status of anti-SARS agents

1 reference

12 December 2020

Identifiers

DOI

10.1586/14787210.4.2.291

1 reference

14 August 2017

0 references

1 reference

PubMed ID

16597209